Wed, Jul 23, 2014, 9:14 AM EDT - U.S. Markets open in 16 mins.


% | $
Click the to save as a favorite.

CryoLife Inc. Message Board

thebuckeye777 8 posts  |  Last Activity: Jul 14, 2014 1:21 PM Member since: Jul 28, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Any view on the CEO announcement?

    by darv222 Jul 10, 2014 2:02 PM
    thebuckeye777 thebuckeye777 Jul 14, 2014 1:21 PM Flag

    I'm delighted by the announcement of PM as the future CEO and President of CRY! What I like about him most besides his impressive business experience is his graduation from West Point. I think the service academies are by far the toughest colleges in America because in addition to an extremely rigorous college curriculum the cadets have numerous military duties.
    I have investments in two other companies where the CEO attended a service college, JNJ and CKP. Alex Gorsky at JNJ has totally reinvigorated the company! ( The prior CEO was asleep at his job in comparison.) CKP has been totally restricted under George Babich and is in the process of a major turnaround.( In CkP's case it helps that the Chairman, William Antle, is a graduate of the Naval Academy has a Harvard MBA is a Bain & Co. alumni and built Oak Industries as its CEO before the sale to Motorola for about 3 billion.)
    In my not so humble opinion you can't ask for a better background for a CEO that a service academy graduate. These guys tend to get more positive things by noon in one day that some other Ceo's get done in a week. Like dhild says it will take time for CRY to develop but I'm very encouraged by the announcement of PM as the future CEO of CRY!

  • Reply to


    by dlhild Jun 17, 2014 1:53 AM
    thebuckeye777 thebuckeye777 Jun 19, 2014 10:45 AM Flag

    My first thought is I sold my COV too soon. ( Got that as I bought TYC at the bottom in 2002 when it was in the 8s.) Second thought is the combination will probably go through as there isn't that much overlap. Three, I doubt that merger with CRY would now be in the cards as this a huge deal and would take a long time to digest. 4th thought is consolidation in the industry will continue as it makes economic sense. I think CRY could still participate.

  • Reply to

    Re-Thinking the Buy-Out Possibility:

    by dlhild May 21, 2014 4:41 PM
    thebuckeye777 thebuckeye777 Jun 1, 2014 5:56 PM Flag

    I just checked Value Line again and CRY is rated in the top 70 of 1700 companies they follow as far as long term appreciation potential at today's price of the stock.

  • Reply to

    Re-Thinking the Buy-Out Possibility:

    by dlhild May 21, 2014 4:41 PM
    thebuckeye777 thebuckeye777 Jun 1, 2014 5:46 PM Flag

    CRY has a lot of hoops to jump through if it stays independent but Value Line has earnings going up to $.90 per share in 2017 to 2019 time frame with a target price range of 16 to 25 which is considerably higher than the average appreciation potential of the 1700 companies they follow.

  • thebuckeye777 by thebuckeye777 May 15, 2014 11:38 AM Flag

    These guys a doing a great job and the future is only going to get a lot better! Strong cash flow is very positive.

  • Reply to

    Question for dlhild

    by darv222 Apr 30, 2014 6:00 PM
    thebuckeye777 thebuckeye777 May 1, 2014 2:19 PM Flag

    I'm looking at the free cash flow long term growth of the business. Besides the US, the company is expanding in Europe, Latin America and Asia.
    I'm not counting on it but a buyout at a substantial premium to today prices is possible , too especially when you look at SA's age. There have been 3 that I know of in the last 5.5 years related to hemostasis type products . The first was Ormrix Biopharmaceuticals in Dec of 2008 for $408,000,000 by JNJ. Their main products were 3 liquid based hemostasis type products that had very small sales but just got FDA approval. I think you should be aware of the other two. From my standpoint the most likely buyer would be Covidien. In 1998 way before Covidien was spun off from Tyco, Tyco bought US Surigical for 3 billion. On of the main things US Surgical does is provide all kinds of surgical staples and stapling machines. CRY's products would be a perfect fit with COV.
    Unlike dlhild, I think CRY's other products have some value but he is right that bioglue and perclot are by far the most valuable products. They contribute to the free cash flow of the business and require little capital investment. The Hero Graft and tissue businesses are also one of a kind businesses which attract some of the leading cardiovascular surgeons in the world to CRY's hemostasis products.

  • That was a pretty powerful CC when you look to the future of the company. Topical approval of Perclot by the FDA is a big deal and I like the fact that CRY is taking it to Bard in the form of a declaratory judgment regarding their patent.

  • thebuckeye777 by thebuckeye777 Apr 28, 2014 10:41 AM Flag

    To me the most important financial metric that CRY has shown over the years is free cash flow generation which is significantly higher than net income. In the 2017 to 2019 time frame Value Line estimates that CRY's free cash flow will be $1.40 per share!

9.07Jul 22 4:02 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.